Silvia M. Illamola

Dr. Silvia M. Illamola


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RLRachel A. Kudgus Lokken
Rachel A. Kudgus Lokken
Silvia M. IllamolaSilvia M. Illamola
Silvia M. Illamola
Kathleen JobKathleen Job
Kathleen Job
HAHesham Al-Sallami
Hesham Al-Sallami
GJGeert W. ‘T Jong
Geert W. ‘T Jong
Catherine SherwinCatherine Sherwin
Catherine Sherwin
Background/Objectives: Selecting appropriate doses for pediatric patients remains one of the most complex challenges in drug development because developmental changes in physiology, metabolism, organ function, and pharmacodynamics substantially influence drug exposure and response. This review summarizes current evidence-based approaches to pediatric dose selection across the developmental continuum and evaluates contemporary model-informed strategies for individualized dosing. Methods: A narrative review of the literature was conducted focusing on pediatric dose-scaling methodologies, developmental pharmacology, physiologically based pharmacokinetic (PBPK) modeling, population pharmacokinetic (PopPK) approaches, exposure–response analysis, therapeutic drug monitoring, and regulatory extrapolation frameworks. Special populations and clinical scenarios relevant to pediatric dose optimization were also evaluated. Results: Simple body weight-based scaling from adult doses inadequately accounts for developmental changes in drug disposition and response. Allometric scaling combined with maturation functions provides improved dose prediction in neonates and infants, while PBPK and PopPK modeling support mechanistic and data-driven dose optimization across pediatric age groups. Fat-free-mass (FFM)-based scaling is preferred over total body weight for many drugs in children with obesity. Additional considerations including obesity, biologics, formulation and excipient safety, pharmacogenomics, critical illness, therapeutic hypothermia, extracorporeal support, therapeutic drug monitoring, and drug–drug interactions substantially influence pediatric dosing strategies. Regulatory frameworks including ICH E11A increasingly support model-informed pediatric extrapolation and precision dosing approaches. Conclusions: Pediatric dose selection has evolved from empirical weight-based dosing toward integrated model-informed strategies incorporating developmental physiology, pharmacometrics, and regulatory science. Allometry, maturation functions, FFM-based scaling, PBPK, PopPK, and therapeutic drug monitoring provide complementary tools for rational pediatric dose optimization, although drug- and pathway-specific validation remains essential, particularly in neonates and critically ill children.

1 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAnan Chanruang
Anan Chanruang
ABAngela Birnbaum
Angela Birnbaum
Silvia M. IllamolaSilvia M. Illamola
Silvia M. Illamola
SSSasithorn Sirilun
Sasithorn Sirilun
Suthunya ChupraditSuthunya Chupradit
Suthunya Chupradit
BPBaralee Punyawudho
Baralee Punyawudho
Background/Objectives: Despite its role as a first-line therapy for Thai people living with HIV (PLWH), dolutegravir (DTG) exhibits significant pharmacokinetic (PK) variability influenced by both genetic and non-genetic factors. This variability may contribute to an increased incidence of neuropsychiatric adverse events (NP-AEs) at the standard 50 mg once daily (OD) dose. Methods: To evaluate the impact of relevant covariates, a population PK model of DTG was developed using 1122 DTG plasma concentrations from 221 Thai PLWH. Monte Carlo simulations were performed to evaluate the probability of target attainment for pre-defined efficacy and safety thresholds across different dosage regimens. Results: Data were analyzed using a one-compartment model with first-order absorption incorporating lag-time, and first-order elimination. Body weight ( 95% of the population but resulted in a substantial proportion (30.46–85.68%) exceeding the safety threshold. In contrast, a reduced dose of 25 mg OD maintained high efficacy target attainment (>80%) while decreasing the proportion exceeding the safety threshold to <20% in most subgroups. Conclusions: These findings suggest that a reduced DTG dose may be a suitable alternative for Thai PLWH to mitigate the risk of NP-AEs, particularly among individuals with low body weight carrying the combined UGT1A1 and NR1I2 variants.